Clinical Trial

Emapalumab Prevention of CAR-T Cell Associated Toxicities

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated November 14, 2025 (before its estimated August 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This research study involves assessing the impact of emapalumab as preventative management of CAR-T related cytokine release syndrome in participants with Non-Hodgkin's lymphoma (NHL). The research study involves the following study interventions: * Fludarabine and cyclophosphamide (Lymphodepleting Chemotherapy) * Axicabtagene Ciloleucel * Emapalumab
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-08-08; most recent amendment 2025-11-12.
Status change: Not Yet Recruiting → Recruiting 2024-12-16
Trial Details
NCT Number NCT06550141
Lead Sponsor Marcela V. Maus, M.D.,Ph.D.
Collaborators: Swedish Orphan Biovitrum
Conditions Large B-cell Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma
Enrollment 28 participants
Start Date 2024-09-18
Primary Completion 2026-08-01 (estimated)
Study Completion 2027-08-01 (estimated)
Updated on ClinicalTrials.gov 2025-11-14